Nurix Therapeutics Gets FDA Fast-Track Designation for NX-5948
By Sabela Ojea
Nurix Therapeutics said the Food and Drug Administration has granted fast-track designation for NX-5948, its treatment for certain types of lymphocytic cancer.
NX-5948 is a degrader of Bruton's tyrosine kinase and is being studied to treat relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
The clinical-stage biopharmaceutical company on Tuesday said the designation follows encouraging safety and efficacy data from its ongoing Phase 1 clinical trial.
The FDA's fast-track designation is aimed at facilitating and expediting the development and review of drug candidates.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 16, 2024 16:33 ET (21:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks